Arix Bioscience PLC (ARIX)
Correction: Result of Annual General Meeting
24-May-2023 / 07:00 GMT/BST
The following amendment has been made to the ‘Arix Bioscience plc Result of Annual General Meeting' announcement released on 23/05/2023 at 16:30 under EQS News ID 1639935.
Website links to the full details of the Arix investor relations website and National Storage Mechanism have been reinserted, owing to a text conversion error on the EQS platform.
All other information remains unchanged. The fully amended text is shown below:
Arix Bioscience plc
Result of Annual General Meeting
LONDON, 24 May 2023:Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces that at its Annual General Meeting (the "Meeting") duly convened and held today, all resolutions as set out on the notice of meeting were duly passed by way of a poll. Resolutions 1 to 11 were passed as ordinary resolutions. Resolutions 12 to 15 were passed as special resolutions.
Full details of the poll results are set out below and will also be available on the Company'swebsite at: https://arixbioscience.com/investor-relations/document-library?folder=AGM&year=
No |
RESOLUTION |
VOTES FOR |
% |
VOTES AGAINST |
% |
TOTAL VOTES |
% of ISC VOTED |
VOTES WITHHELD |
1 |
To receive the Directors' Report and the accounts of the Company for the year ended 31 December 2022 |
68,931,411 |
100.00% |
3,441 |
0.00% |
68,934,852 |
53.28% |
8,440 |
2 |
To approve the Directors' Remuneration Report |
61,073,950 |
89.25% |
7,358,207 |
10.75% |
68,432,157 |
52.89% |
511,135 |
3 |
To re-elect Peregrine Moncreiffe as a Director |
68,099,019 |
98.79% |
834,821 |
1.21% |
68,933,840 |
53.28% |
9,452 |
4 |
To re-elect Maureen O'Connell as a Director |
68,894,053 |
99.94% |
42,077 |
0.06% |
68,936,130 |
53.28% |
7,162 |
5 |
To re-elect Isaac Kohlberg as a Director |
68,900,656 |
99.98% |
17,184 |
0.02% |
68,917,840 |
53.26% |
25,452 |
6 |
To re-elect Robert Lyne as a Director |
68,902,689 |
99.95% |
31,595 |
0.05% |
68,934,284 |
53.28% |
9,008 |
7 |
To elect Dr. Debra Barker as a Director |
68,907,528 |
99.95% |
32,248 |
0.05% |
68,939,776 |
53.28% |
3,516 |
8 |
To elect Andrew Smith as a Director |
68,921,195 |
99.98% |
13,089 |
0.02% |
68,934,284 |
53.28% |
9,008 |
9 |
To appoint BDO LLP as auditors of the Company |
68,929,881 |
99.99% |
7,445 |
0.01% |
68,937,326 |
53.28% |
5,966 |
10 |
To authorise the Audit and Risk Committeeof the Company to fix the auditor's remuneration |
68,934,245 |
100.00% |
2,013 |
0.00% |
68,936,258 |
53.28% |
7,034 |
11 |
To authorise the Directors to allot shares |
65,989,256 |
95.72% |
2,950,520 |
4.28% |
68,939,776 |
53.28% |
3,516 |
12 |
Authority to disapply statutory pre‐ emption rights |
62,199,252 |
90.23% |
6,734.680 |
9.77% |
68,933,932 |
53.28% |
9,360 |
13 |
Additional authority to disapply statutory pre‐ emption rights |
62,202,105 |
90.23% |
6,731,827 |
9.77% |
68,933,932 |
53.28% |
9,360 |
14 |
To authorise the Company to purchase its own shares |
68,921,128 |
99.98% |
17,177 |
0.02% |
68,938,305 |
53.28% |
4,987 |
15 |
Authority to call a general meeting, other than an annual general meeting, on not less than 14 clear days' notice |
68,145,351 |
98.85% |
792,954 |
1.15% |
68,938,305 |
53.28% |
4,987 |
In accordance with Listing Rule 9.6.2, copies of resolutions passed at the Meeting concerning items other than ordinary business will shortly be available for inspection on the National Storage Mechanism, which can be accessed here: https://data.fca.org.uk/#/nsm/nationalstoragemechanism
The full text of the resolutions considered at the AGM are contained in the Notice of AGM, published on25 April 2023, which is available on Arix investor relationswebsite at: https://arixbioscience.com/investor-relations/document-library?folder=AGM&year=
[ENDS]
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
+44 (0)20 7290 1050
Powerscourt Group
Sarah MacLeod,Ibrahim Khalil, Nick Johnson
+44 (0)20 7250 1446
About Arix Bioscience plc
Arix Bioscience plc is a transatlantic venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise, and networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
| ISIN: | GB00BD045071 |
| Category Code: | RAG |
| TIDM: | ARIX |
| LEI Code: | 213800OVT3AHQCXNIX43 |
| OAM Categories: | 3.1. Additional regulated information required to be disclosed under the laws of a Member State |
| Sequence No.: | 245808 |
| EQS News ID: | 1639987 |
| End of Announcement | EQS News Service |
==